RxDoctor Payments Data

Joseph Armenia, MD

Ophthalmic Plastic and Reconstructive Surgery · Webster, NYNPI 1770840720

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $32,805 of the $38,415 with a category attached, or 85.4%. Amgen accounts for 99.6% of it on its own, with 1 other manufacturer making up the rest. 2025 is the largest year on record at $10,862, more than ten times the $158 reported in 2020.

$38,415in general payments, 2019–2025

Across 94 payments — averaging $408.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$38K
  • Alcon$156

What the payments were for

  • Consulting fees$8502%
  • Speaking & faculty fees$32,80585%
  • Travel & lodging$6292%
  • Food & beverage$4,10811%
  • Education$240%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)92$38,260
Alcon2$156

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,415 in reported general payments places this provider in the 80th percentile of 25 ophthalmic plastic and reconstructive surgery providers in New York.

See all ophthalmic plastic and reconstructive surgery providers in New York

Medicare billing

Part B allowed, 2024
$80,370
Medicare patients
138
Services billed
1,534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha482$5,907
Prednisolone Acetate12$586
Doxycycline Hyclate18$449
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen261$324
Methylprednisolone22$289
ErythromycinErythromycin Base18$194
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim15$105

Paid to pharmacies, not to this prescriber.

Other ophthalmic plastic and reconstructive surgery in Webster

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →